A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
A phase 2 trial of [177Lu]Lu-PSMA-617 in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Overview
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer is a phase 2 interventional study registered as NCT05658003 by Novartis Pharmaceuticals, with 63 participants enrolled, started 2023-05-05 and due to reach its primary completion in 2024-12-02. Interventions recorded: [177Lu]Lu-PSMA-617, ARDT and [68Ga]Ga-PSMA-11.
Similar pages
not linked directly; found by shared links- TrialA Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Shares Advanced Accelerator Applications (Novartis), Metastatic castration-resistant prostate cancer, Prostate cancer, Lutetium-177 and the tag pipeline.
- TrialA Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Shares Metastatic castration-resistant prostate cancer, Gallium-68, Prostate cancer, Lutetium-177 and the tag pipeline.
- TrialA Study of 177Lu-FAP-2286 in Advanced Solid Tumors
Shares Advanced Accelerator Applications (Novartis), Gallium-68, Lutetium-177 and the tag pipeline.
- TrialStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Shares Advanced Accelerator Applications (Novartis), Lutetium-177 and the tag pipeline.
- TrialA Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Shares Metastatic castration-resistant prostate cancer, Prostate cancer, Lutetium-177 and the tag pipeline.
- TrialA Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Shares Advanced Accelerator Applications (Novartis), Gallium-68, Lutetium-177 and the tag pipeline.
- TrialA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Shares Advanced Accelerator Applications (Novartis), Prostate cancer and the tag pipeline.
- TrialA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.